Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years Genentech, 19 Oct 2011 Accessed on 5 Dec 2011 from http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13627. CommentRecommendBookmarkWatch